From the Journals

Pneumonia risk soars in heart failure patients, especially HFpEF


 

FROM JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vaccination crucial in HF patients

Dr. McMurray noted that this study emphasizes the importance of pneumonia vaccination for patients with HF. “Given that we have so few treatments to offer patients with HFpEF, this makes the potential value of vaccination in these patients all the greater,” he said.

The COVID-19 pandemic, Dr. McMurray said, is a “good reminder of the dangers of a respiratory infection and the importance of vaccination in these patients. COVID-19 has interesting parallels in being a systemic disease and one with postacute, persisting effects.”

The persistent risk for adverse cardiovascular events 3 months and later after pneumonia is a novel finding of the study, wrote Donna Mancini, MD, and Gregory Gibson, MD, in an invited commentary (J Am Coll Cardiol. 2021;77:1974-6). Both are with the Icahn School of Medicine at Mt. Sinai in New York. The post hoc study also “serves as an important reminder” of pneumonia risk in patients with HF, especially during the pandemic, they wrote.

“Although vaccination alone appears unlikely to be a panacea, it is a readily accessible tool for mitigating disease severity and improving outcomes,” Dr. Mancini and Dr. Gibson wrote. “After all, an ounce of prevention is worth a pound of cure.”

Novartis provided funding for the PARADIGM-HF and PARAGON-HF trials, and Dr. McMurray and coauthors disclosed financial relationships with Novartis. Dr. Mancini and Dr. Gibson have no relevant financial relationships to disclose.

Pages

Recommended Reading

Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
The Hospitalist
Myocarditis by CMR may be rare after COVID-19 in elite athletes
The Hospitalist
Neprilysin, corin singled out for potential to guide heart failure therapy
The Hospitalist
Newer iPhones disable implanted defibrillators
The Hospitalist
Cardiac activity not uncommon after lifesaving measures stop
The Hospitalist
More Americans hospitalized, readmitted for heart failure
The Hospitalist
FDA expands sacubitril/valsartan indication to embrace some HFpEF
The Hospitalist
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
The Hospitalist
Heart failure redefined with new classifications, staging
The Hospitalist
Inpatient sodium imbalances linked to adverse COVID-19 outcomes
The Hospitalist
   Comments ()